NSCLC Cancer Populations USA 2026–2046

How many newly diagnosed cases of NSCLC are there in the United States?

• In 2027, using estimates published by SEER (citation), X people will be diagnosed with NSCLC in the USA. X% of these will not receive curative treatment due to the extent of disease or other factors such as a patient's age and comorbidities.
• In 2027 a further X will develop inoperable disease following recurrence of NSCLC that was first diagnosed at an earlier stage. The resulting total number of patients eligible for treatment of advanced NSCLC is therefore X.
• Of the X people diagnosed with advanced NSCLC in the US, X% will receive some form of anti-cancer drug treatment, representing X cases in 2027
• Of the X people diagnosed with advanced NSCLC in the US, X% will receive some form of anti-cancer drug treatment, representing X cases in 2027

This model employs a validated epidemiological forecasting framework drawing on data from SEER, NCI, and proprietary sources. Incidence projections are derived using age-period-cohort (APC) modeling, while prevalence estimates incorporate survival rate adjustments from published clinical literature and real-world evidence datasets.

Forecast uncertainty is expressed through probabilistic ranges at 80% and 95% confidence intervals. Scenario analyses are provided for optimistic, base case, and conservative assumptions across key modeling parameters.